Victory Capital Management Inc. Has $28.22 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Victory Capital Management Inc. grew its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 23.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 253,299 shares of the specialty pharmaceutical company's stock after purchasing an additional 47,807 shares during the period. Victory Capital Management Inc. owned approximately 0.41% of Jazz Pharmaceuticals worth $28,220,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. CWA Asset Management Group LLC bought a new stake in shares of Jazz Pharmaceuticals in the third quarter worth about $3,197,000. Swedbank AB purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at $106,936,000. Vanguard Group Inc. boosted its position in shares of Jazz Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company's stock valued at $776,551,000 after buying an additional 84,941 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Jazz Pharmaceuticals by 25.5% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 33,219 shares of the specialty pharmaceutical company's stock worth $4,000,000 after buying an additional 6,756 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp lifted its stake in Jazz Pharmaceuticals by 131.9% during the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 73,757 shares of the specialty pharmaceutical company's stock valued at $8,818,000 after acquiring an additional 41,950 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Neena M. Patil sold 3,700 shares of the firm's stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares in the company, valued at $1,573,707.30. This represents a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,110 shares of company stock worth $720,160 in the last 90 days. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Trading Down 3.3 %

NASDAQ JAZZ traded down $4.06 during trading hours on Monday, hitting $117.59. 646,680 shares of the company's stock were exchanged, compared to its average volume of 678,484. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.17. The business's 50 day moving average is $112.22 and its 200-day moving average is $110.35. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market capitalization of $7.11 billion, a P/E ratio of 17.03, a price-to-earnings-growth ratio of 1.02 and a beta of 0.57.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Royal Bank of Canada increased their price objective on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 23rd. Wells Fargo & Company dropped their target price on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating for the company in a report on Thursday, August 1st. Robert W. Baird lifted their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an "outperform" rating in a report on Monday. HC Wainwright restated a "buy" rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Finally, Needham & Company LLC reissued a "buy" rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $175.53.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.